Newswise — John Sweetenham, MD, professor of medicine and former vice chair and director of clinical research at the Cleveland Clinic Taussig Cancer, part of Case Comprehensive Cancer Center, has been named medical director at UC San Diego Nevada Cancer Institute.
“As medical director, Dr. Sweetenham will advance personalized, research-driven treatment strategies to meet the needs of individual patients,” said Thomas McAfee, MD, dean of clinical affairs at UC San Diego Health System. “Under his leadership, UC San Diego Nevada Cancer Institute will become a top destination for cancer care in Nevada, and a tremendous community partner in growing the state’s health care infrastructure.”
An international expert in malignant lymphomas, Sweetenham has authored more than 150 peer-reviewed articles, and served as principal investigator on national and international lymphoma clinical trials. He currently co-chairs the Eastern Cooperative Oncology Group Lymphoma Committee and serves as chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research. He has been a committee member of the American Society of Clinical Oncology and the American Society of Hematology.
Sweetenham studied at the St. Bartholomew and Royal London School of Medicine and graduated from the University of Southhampton where he also completed his fellowship in medical oncology. He completed his internship at St. Bartholomew’s Hospital and his residency at Royal Berkshire Hospital.
Prior to joining the UC San Diego Nevada Cancer Institute, Sweetenham was director of clinical research at Cleveland Clinic. He previously served as associate director for clinical research at the University of Arizona, and as director of the Hematologic Malignancies and Blood and Marrow Transplant programs at the University of Colorado.
In addition to his responsibilities in clinical administration, program development and clinical trials leadership, Sweetenham plans to maintain an active clinical practice at Nevada Cancer Institute. As a clinician, he has been honored by both health industry peers and independent rating organizations, named in the publication Best Doctors in America every year since 2003, and both Castle Connolly’s America’s Top Doctors and America’s Top Doctors for Cancer every year since 2009. He was also recently honored in U.S. News World Report’s “Top Doctors.”
UC San Diego Nevada Cancer Institute is part of UC San Diego Health System in California. Launched in 1966, UC San Diego Health System is an academic health system, with a mission of providing excellent and compassionate patient care, advancing medical discoveries and educating future health care professionals. It comprises UC San Diego Medical Center in Hillcrest, and UC San Diego Thornton Hospital, Moores Cancer Center, Shiley Eye Center, Sulpizio Cardiovascular Center and Jacobs Medical Center (slated to open in 2016) in La Jolla, as well as other primary and specialty practices of UC San Diego Medical Group.
UC San Diego Nevada Cancer Institute is committed to reducing the burden of cancer by offering the best in high-quality, innovative and collaborative patient care, clinical trials and community education. Part of the UC San Diego Health System, the Institute operates two locations in Southern Nevada – the main treatment center in Summerlin and a clinic at University Medical Center in downtown Las Vegas.